Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 9:21 PM
Ignite Modification Date: 2025-12-24 @ 9:21 PM
NCT ID: NCT00760604
Eligibility Criteria: Inclusion Criteria: * Patients with cT2-T3/N0-N1-M1a-M1b(lymph node metastasis only) esophageal squamous cell and adenocarcinoma who have potentially resectable disease. * Karnofsky performance status greater than or equal to 80%. * Pulmonary and cardiac function must be acceptable for surgery according to institutional standards. * Acceptable hepatic, renal and bone marrow function. * Age 18 or older. * Patients may receive preoperative chemotherapy and/or radiation therapy as part of their clinical care. Exclusion Criteria: * Patients with clearly unresectable or metastatic esophageal cancer or clinical stage I esophageal cancer. * Significant psychiatric illness that would interfere with patient compliance. * Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment. * Patients with a significant history of unstable cardiovascular disease (e.g., inadequately controlled hypertension, or angina; myocardial infarction within the previous 6 months; ventricular cardiac arrhythmias requiring medication; congestive heart failure that in the opinion of the treating physician should preclude the patient from protocol treatment. * Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or interstitial pneumonia or interstitial fibrosis.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 85 Years
Study: NCT00760604
Study Brief:
Protocol Section: NCT00760604